The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Biomaterials for mRNA delivery
Open accessAbstract
Messenger RNA (mRNA) has recently emerged with remarkable potential as an effective alternative to DNA-based therapies because of several unique advantages. mRNA does not require nuclear entry for transfection activity and has a negligible chance of integrating into the host genome which excludes the possibility of potentially detrimental genomic alternations. Chemical modification of mRNA has further enhanced its stability and decreased its activation of innate immune responses. Additionally, mRNA has been found to have rapid expression and predictable kinetics. Nevertheless, the ubiquitous application of mRNA remains challenging given its unfavorable attributes, such as large size, negative charge and susceptibility to enzymatic degradation. Further refinement of mRNA delivery modalities is therefore essential for its development as a therapeutic tool. This review provides an exclusive overview of current state-of-the-art biomaterials and nanotechnology platforms for mRNA delivery, and discusses future prospects to bring these exciting technologies into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Different non-viral materials have been designed and optimized for accommodating efficient delivery of diverse RNA molecules as well as multi-component genome editing systems.[22, 34–36]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
In the citing paper
“For many GARDs, the liver is a preferred organ for mRNA-based PRTs because systemically administrated mRNA vehicles are predominantly trapped by the reticuloendothelial system (RES) in the liver.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
In the citing paper
“In addition, the interaction between apolipoprotein E (apoE) and biomaterials such as lipid and lipid derived materials facilitates the accumulation in the liver.[8, 18, 34, 39, 59, 120, 121, 124, 164, 165]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Shaw, G. D., & Kamen, R. (1986) · Cell · doi:10.1016/0092-8674(86)90341-7 · Cited by 3,946
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Gold Nanoparticles for Biology and Medicine
Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., & Mirkin, C. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904359 · Cited by 2,389
Flagged first, then by citations
Research works printed but not linked: 13
- Quabius, 2015, Nat. Biotechnol., 32, 229
- Stepinski, 2001, RNA, 7, 1486
- Mattozzi, 2014, J. Vis. Exp., 86, e51234
- Dewitte, 2014, J. Controlled Release, 194c, 28, 10.1016/j.jconrel.2014.08.011 · DOI
- Koch, 1973, Curr. Top. Microbiol. Immunol., 62, 89
- Pasquinelli, 1995, RNA, 1, 957
- K. J. Kallen and A.Thess, Therapeutic Advances in Vaccines, 2014, vol. 2, pp. 10–31
- Sebastian, 2012, J. Clin. Oncol., 2012, 30
- Zhang, 2008, ACS Nano, 2, 1696, 10.1021/nn800275r · DOI
- Salvador-Morales, 2009, Biomaterials, 30, 2231, 10.1016/j.biomaterials.2009.01.005 · DOI
- Su, 2011, Mol. Pharm., 8, 774, 10.1021/mp100390w · DOI · Paper page
- Conry, 1995, Cancer Res., 55, 1397
- Anderson, 2003, Hum. Gene Ther., 14, 191, 10.1089/10430340360535751 · DOI · Paper page
Cited by
Sorted by citations
Items 101–176 of 176
Sharifnia, Z., Bandehpour, M., Hamishehkar, H., Mosaffa, N., Kazemi, B., & Zarghami, N. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100872 · Cited by 26
Raynold, A. A. M., Li, D., Chang, L., & Gautrot, J. E. (2021) · Nature Communications · doi:10.1038/s41467-021-26695-w · Cited by 25
Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers
Wang, H., Liu, X., Ai, X., Remant-Bahadur, K. C., Dick, T. A., Yan, B., Lu, T., Zhou, X., Luo, R., Liu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020410 · Cited by 25
Liu, Y., Chen, J., Tang, Y., Li, S., Dou, Y., & Zheng, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00549 · Cited by 27
İmani, S., Tagit, O., & Pichon, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00807-1 · Cited by 25
RetractedPuhl, D. L., Funnell, J. L., Fink, T. D., Swaminathan, A., Oudega, M., Zha, R. H., & Gilbert, R. J. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.025 · Cited by 24
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Development of mRNA vaccines and their prophylactic and therapeutic applications
Lee, K., Kim, M., Seo, Y., & Lee, H. (2018) · Nano Research · doi:10.1007/s12274-018-2095-8 · Cited by 23
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
Huang, Y., Cao, R. Y., Wang, S., Chen, X., Yü, P., & Zhang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2558403 · Cited by 19
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
Poly(glycoamidoamine) brush nanomaterials for systemic siRNA delivery in vivo
Luo, X., Wang, W., Dorkin, J. R., Omid Veiseh, A., Chang, P., Ionita, I. A., Danino, D., Langer, R., Anderson, D. G., & Dong, Y. (2016) · Biomaterials Science · doi:10.1039/c6bm00683c · Cited by 18
Lipid-Polyhydroxyalkanoate Hybrid Nanoparticles as Sustainable Platform for mRNA delivery
Mazrad, Z. A. I., Lee, C. L., Zhang, T., Warne, N. M., Huynh, N. T., Nur‐A‐Tomal, M. S., Cameron, N. R., Hag, L. V. ‘., Pouton, C. W., & Kempe, K. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114755 · Cited by 18
Current status of nucleic acid therapy and its new progress in cancer treatment
Lou, W., Zhang, L., & Wang, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113157 · Cited by 19
Lv, S., Wu, Y., Dang, J., Tang, Z., Song, Z., Ma, S., Wang, X., Chen, X., Cheng, J., & Yin, L. (2017) · Polymer Chemistry · doi:10.1039/c6py02230h · Cited by 16
Zhao, M. F., Li, J., Ji, H., Chen, D., & Hu, H. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s215250 · Cited by 16
Therapeutic Mechanism of Nucleic Acid Drugs
Liu, L., Gao, H., Guo, C., Liu, T., Li, N., & Qian, Q. (2021) · ChemistrySelect · doi:10.1002/slct.202002901 · Cited by 16
Advances in hybrid exosome-liposome nanoparticles for enhanced cancer therapy
Dou, J., Wang, J., Zhang, G., Fu, X., Zhang, Y., & Sun, F. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115317 · Cited by 15
Egberink, R. O., Zegelaar, H. M., Boujnouni, N. E., Versteeg, E. M. M., Daamen, W. F., & Brock, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081619 · Cited by 15
Monfared, Y. K., Mahmoudian, M., Zakeri‐Milani, P., Cecone, C., Hayashi, T., Ishii, K. J., Conde, J., Matencio, A., & Trotta, F. (2023) · Cancers · doi:10.3390/cancers15143748 · Cited by 15
Oncolytic Virus‐Like Nanoparticles for Tumor‐Specific Gene Delivery
Li, Y., Yang, H., Zong, X., Li, X., Yuan, P., Yang, C., Chen, X., Yan, X., Wen, Y., Zhu, T., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314898 · Cited by 17
Men, K., Zhang, R., Zhang, X., Huang, R., Zhu, G., Tong, R., Yang, L., Wei, Y., & Duan, X. (2018) · RSC Advances · doi:10.1039/c7ra13656k · Cited by 15
Co-delivery of mRNA and SPIONs through amino-ester nanomaterials
Luo, X. L., Zhao, W., Li, B., Zhang, X., Zhang, C., Bratasz, A., Deng, B., McComb, D. W., & Dong, Y. (2018) · Nano Research · doi:10.1007/s12274-018-2082-0 · Cited by 15
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Rational design of polymer-based mRNA delivery systems for cancer treatment
Wan, Q., Sun, Y., Sun, X., & Zhou, Z. (2024) · Polymer Chemistry · doi:10.1039/d4py00206g · Cited by 15
Zhao, W., Zeng, C., Yan, J., Du, S., Hou, X., Zhang, C., Li, W., Deng, B., McComb, D. W., Xue, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103131 · Cited by 14
Factors Influencing the Delivery Efficiency of Cancer Nanomedicines
Ullah, R., Wazir, J., Khan, F. U., Diallo, M. T., Ihsan, A. U., Mikrani, R., Aquib, M., & Zhou, X. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01691-3 · Cited by 15
Plasmid DNA and mRNA delivery: Approaches and challenges
Singh, A. K., Goel, K., & Dhanawat, M. (2025) · Advances in immunology · doi:10.1016/bs.ai.2024.12.001 · Cited by 13
Jiang, B., He, H., Li, Y., Zhang, T., Huo, J.-P., Sun, W., & Yin, L. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01774 · Cited by 13
miR-4299 inhibits tumor progression in pancreatic cancer through targeting ADAM17
Liu, J., Ye, L., Lin, K., Zhong, T., Luo, J., Wang, T., Suo, L., Mo, Q., Li, S., Chen, Q., et al. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04617-8 · Cited by 12
Hyperbranched Polymer‐Based Vaccines for Cancer Immunotherapy
Wang, Z., Guo, Y., Shen, M., Wang, Y., & Shi, X. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300188 · Cited by 11
Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00821-z · Cited by 11
Alazzo, A., Lovato, T., Collins, H. M., Taresco, V., Stolnik, S., Soliman, M. E., Spriggs, K. A., & Alexander, C. (2018) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.36 · Cited by 11
Recent Advances in Biomaterials for mRNA Delivery to Immune Cells
Isaac, I., Bhatia, M., & Bhattacharya, C. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00734 · Cited by 10
Alazzo, A., Alnatour, M., Spriggs, K. A., Stolnik, S., Ghaemmaghami, A. M., Kim, D., & Alexander, C. (2019) · Molecular Omics · doi:10.1039/c8mo00139a · Cited by 10
Xie, D., Chen, X., Wu, H., Ning, D., Cao, X., & Wan, C. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s390770 · Cited by 10
Hu, Y., Tang, Y., Zhang, X., Yang, X., Tang, Y., Li, S., Hu, L., Chen, P., & Zhu, D. (2020) · Biomaterials Science · doi:10.1039/d0bm00395f · Cited by 10
Hoehn, S. J., Krul, S. E., Skory, B. J., & Crespo‐Hernández, C. E. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103667 · Cited by 9
Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer
Song, Q., Zheng, Y., Zhong, G., Wang, S., He, C., & Li, M. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206323900240807110122 · Cited by 11
Rapid formulation of redox-responsive oligo-β-aminoester polyplexes with siRNA via jet printing
Lovato, T., Taresco, V., Alazzo, A., Sansone, C., Stolnik, S., Alexander, C., & Conte, C. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01215f · Cited by 9
da Silva-Filho, C. J. A., de Freitas, P. G. C., Oliveira, F. C. E., Barbosa, F. G., de Oliveira, M. D. C. F., Eloy, J. O., Pessoa, C., & Mafezoli, J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127469 · Cited by 9
Car-T Cell Therapy: Current Advances and Future Research Possibilities
Ahmed, M. M. E. (2021) · Journal of Scientific Research in Medical and Biological Sciences · doi:10.47631/jsrmbs.v2i2.234 · Cited by 11
Nana, S., Govender, M., & Choonara, Y. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040470 · Cited by 7
Supramolecular Gene Transfection Agents
Pitard, B., & Habrant, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12563-6 · Cited by 8
Peptide modified polycations with pH triggered lytic activity for efficient gene delivery
Chen, X., Xu, K. L., Yu, J. X., Zhao, X., Zhang, Q., Zhang, Y., & Cheng, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01231a · Cited by 7
Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection
Kisakov, D. N., Kisakova, L. A., Sharabrin, S. V., Yakovlev, V. A., Tigeeva, E. V., Borgoyakova, M. B., Starostina, E. V., Zaikovskaya, A. V., Рудометов, А. П., Борисовна, Р. Н., et al. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06107-x · Cited by 6
Zhang, X., Chen, J., Han, S., Dong, S., Zhang, H., Man, Y., Yang, J., Bi, Y., & Teng, L. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109668 · Cited by 4
mRNA Delivery Systems Based on Protein Nanocages: How Far Can We Go?
Wang, X., Gao, R., Wang, X., Zhou, J., Zhang, X., & Li, F. (2024) · BioDesign Research · doi:10.34133/bdr.0032 · Cited by 5
Hybridization Networks of mRNA and Branched RNA Hybrids
Damakoudi, V., Feldner, T., Dilji, E., Belkin, A., & Richert, C. (2020) · ChemBioChem · doi:10.1002/cbic.202000678 · Cited by 3
Aşı Teknolojisinde Yeni Umutlar: mRNA Aşıları
Yılmaz, E. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20219912 · Cited by 7
Moderne Konzepte der Nanobiotechnologie für mRNA‐Abgabesysteme
Wang, Y., & Yu, C. (2020) · Angewandte Chemie · doi:10.1002/ange.202003545 · Cited by 4
Anhydrous proton-conducting material consisting of basic protein protamine
YAMADA, M., Sugihara, T., & Yamada, T. (2021) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2021.115586 · Cited by 4
Development and optimisation of cationic lipid nanoparticles for mRNA deliveryPreprint
Yan, D., Lu, H., Kaur, A., Fu, R., Wang, N., Teh, J. H., Lou, H., Aboagye, E. O., & Chen, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.07.524134 · Cited by 3
Gao, W., An, K., Ma, Y., Xu, X., Wang, Z., Liu, J., Shan, X., Liu, Y., Chen, W., Wang, P., et al. (2025) · Advanced Materials · doi:10.1002/adma.202512235 · Cited by 2
Recent approaches of proliposome-based dry powder inhalation for pulmonary delivery
Havelikar, U. A., Magar, S. B., Teharke, A. K., & Chaudhari, N. B. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108053 · Cited by 2
Redox-responsive nanoparticles for enhanced mRNA delivery: a comprehensive review
Wang, Z., Chen, B., (24124354), Y. G., Wu, C., Shuai, Q., & Yan, Y. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00186f · Cited by 2
Critical chemistry manufacturing and controls considerations for mRNA lipid nanoparticle translation
Liu, L., Wang, Y., Gao, H., Ruan, J., Lu, W., Liu, T., Li, X., Zhang, G., & Xiao, Y. (2026) · Discover Nano · doi:10.1186/s11671-026-04864-4 · Cited by 3
Zhou, Y., Tang, Y., Huang, F., Wang, Z., Wen, Z., Fang, Q., & Wang, C. (2025) · Human Cell · doi:10.1007/s13577-025-01173-3 · Cited by 2
Delivery of Cancer Nanotherapeutics
Chung, B. L., Kaplinsky, J., Langer, R., & Kamaly, N. (2018) · Bioanalysis · doi:10.1007/978-3-030-01775-0_8 · Cited by 2
Nanopharmacology Intervention in Human Pathological Diseases
Matai, I., Garg, D., Gupta, U., & Sachdev, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817830-0.00007-2 · Cited by 2
Fan, C., Wang, S.-W., & Wong, C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.26.572282 · Cited by 2
Progress in mRNA delivery systems based on virus-like particles
Wang, X., Wan, Y., Zhang, X., Xu, C., & Li, F. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0632 · Cited by 1
Sterin, E. H., Weinstein, L. A., Chowdhury, C. R., Guzzetti, E. C., & Day, E. S. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00013k · Cited by 1
Henry, N., Kaur, A., & Chen, R. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2702442 · Cited by 1
mRNA Vaccine: Determinants of Clinical Efficacy, and Optimization of Pharmacological Effects
Ohanube, G. A. K., & Obeta, U. M. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/175q0zatao · Cited by 1
Mantas, A., Metin, C. U., Demir, B. S., Guler, F. N., Mengi, S., Inci, C. C., Kilic, O., Babar, H. A., Ceylaner, G., Ceylaner, S., et al. (2020) · Preprints.org · doi:10.20944/preprints202009.0723.v1
Biomaterials for gene editing therapeutics
Shim, G., Kim, D., Le, Q., Byun, J., Park, J.-W., & Oh, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00008-9
Designed synthesis of silica based nanocarriers for mRNA delivery
Wang, Y. (2020) · The University of Queensland · doi:10.14264/b28d1e7
He, X. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738957376.793579986
Yang, J., Luo, J., Wang, F., Cheng, Z., Han, X., Liu, C., & Wang, Z. (2020) · doi:10.21203/rs.3.rs-27017/v1
Nano-delivery Systems for mRNA: A comprehensive review of lipid-based and polymer-based approaches
Turankar, C. C., Kubde, J. A., Hatwar, P. R., Bakal, R. L., & Mahure, L. D. (2025) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2025.23.1.0107 · Cited by 1
Research progress and challenges in in vivo CAR-T cell therapy
HUANG, Y.-F., & Zhang, Y. (2026) · Shengming kexue · doi:10.3724/cbls.2026074
Polycation chain length determines the in vivo mRNA delivery efficiency of block copolymer micelles
Nakashima, Y., Chen, P., Hu, G., Masuda, K., Takasugi, S., & Cabral, H. (2026) · Biomaterials Science · doi:10.1039/d6bm00820h
Liang, H., Hu, R., Lu, B., Zhang, J., Yang, J., & Zhou, Z. (2026) · Nanoscale · doi:10.1039/d6nr02315k
Next-generation CAR therapies enabled by mRNA engineering and delivery
Zhao, Q., Wen, Q., Pu, P., Xu, C., Hu, Q., Zhou, Z., Hua, X., & Zhang, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.001
李, 仁., Pan, X., & Zhang, T. (2026) · Journal of Biomaterials Applications · doi:10.1177/08853282261494811
Metadata
- Authors
- Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Zetter, Bruce R.
- Shi, Jinjun
- Venue
- Biomaterials Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2015
- Volume
- 3
- Issue
- 12
- Pages
- 1519-1533
- ISSN
- 2047-4830 (ISSN-L)
- 2047-4849
- PMC
- PMC4641793
- OpenAlex
- W1945220000
- Cited by
- 176
- References
- 123
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 27 · 2019: 16 · 2018: 24 · 2017: 13 · 2016: 11
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biomaterials Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (R01 CA37393, R01CA037393, R00CA160350)
- DOD Prostate Cancer Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- mRNA delivery, biomaterials, nanotechnology, mRNA therapeutics, mRNA stability, innate immune response, mRNA degradation, nucleic acid delivery systems
- MeSH terms
- Biocompatible Materials, Biological Transport, Genetic Vectors, Humans, RNA, Messenger, Transfection, Gene Transfer Techniques, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
